Today: September 21, 2024
Today: September 21, 2024

Latest From TOM MURPHY

Business|Economy|Health|News

High insulin prices spur a federal lawsuit against three pharmacy benefit managers

The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for patients

High insulin prices spur a federal lawsuit against three pharmacy benefit managers
Health

Limits to anti-nausea pill coverage wear on cancer patients and doctors

Some cancer patients are hitting coverage limits on a cheap anti-nausea pill that can ward off waves of vomiting after treatment

Limits to anti-nausea pill coverage wear on cancer patients and doctors
Business|Health

Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarter

Eli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker

Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarter
Business|Health

CVS Health cuts its 2024 forecast a third time, dragged down by health insurance struggles

CVS Health has chopped its 2024 forecast for a third time as the health care giant continues to struggle with high utilization in its health insurance business

CVS Health cuts its 2024 forecast a third time, dragged down by health insurance struggles
Business|Health

Drugstores tinker with new looks as their usual way of doing business faces challenges

America’s drugstores are testing smaller locations and more ways to offer care as more store closings loom

Drugstores tinker with new looks as their usual way of doing business faces challenges
Business|Europe|Finance|Health

European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval

Shares of Biogen slid Friday after a European regulatory committee said the Alzheimer’s treatment Leqembi should not receive marketing approval

Health|Science

Do you really have to wait to go swimming after eating?

No, you don't really have to wait 30 minutes after eating to go swimming

Do you really have to wait to go swimming after eating?
Business|Health

UnitedHealth sticks to 2024 outlook despite strong quarter with costs from massive cyberattack high

UnitedHealth topped second-quarter forecasts but remains cautious about the year as it continues to eat costs from a massive cyberattack and deal with rising medical expenses

UnitedHealth sticks to 2024 outlook despite strong quarter with costs from massive cyberattack high
Business|Economy

Walgreens to take a hard look at underperforming stores, could shutter hundreds more

Walgreens is finalizing a plan to fix its business that could result in the closure of hundreds of additional stores in the next three years

Walgreens to take a hard look at underperforming stores, could shutter hundreds more
Health

Drug shortages keep on growing. Older, injectable medicines are among the most vulnerable

Erin Fox has tracked drug shortages for more than 20 years, and she sees no easy solutions for what has become a record run

Drug shortages keep on growing. Older, injectable medicines are among the most vulnerable
Business

Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues

Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first quarter profit

Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues
Business

Cyberattack costs hit UnitedHealth in 1Q that still turns out better than expected

UnitedHealth Group trounced first-quarter expectations even as costs from a cyberattack to its Change Healthcare business ate into its performance

Cyberattack costs hit UnitedHealth in 1Q that still turns out better than expected
Business

Late-year medical costs spike forces Humana to scale back profit expectations for 2023

Shares of Humana are tumbling after the health insurer said it was still dealing with higher-than-expected care costs from its Medicare Advantage customers and it chopped earnings expectations

Late-year medical costs spike forces Humana to scale back profit expectations for 2023
Business

A continuing decline in sales of COVID-19 products clips revenue at Pfizer

Pfizer lost more than $2 billion in the third quarter as an expected COVID-19 product sales decline clipped revenue

A continuing decline in sales of COVID-19 products clips revenue at Pfizer
Business|Economy

Pfizer stays the course on 2024 outlook after delivering better earnings than Wall Street forecast

Pfizer turned in a better-than-expected fourth quarter, boosted by products outside the drugmaker’s slumping COVID-19 vaccine and treatment

Pfizer stays the course on 2024 outlook after delivering better earnings than Wall Street forecast
Business|Economy

UnitedHealth shares tumble after health care giant reports soaring medical costs in 4Q

UnitedHealth Group turned in a better-than-expected fourth quarter but surprised Wall Street with medical costs that soared 16%

UnitedHealth shares tumble after health care giant reports soaring medical costs in 4Q
Business|Economy

Switch from selling COVID-19 drugs on market rather than to governments continues to sting at Pfizer

Pfizer’s forecast for sales of its COVID-19 vaccine and treatment next year falls more than $5 billion short of the Wall Street consensus

Switch from selling COVID-19 drugs on market rather than to governments continues to sting at Pfizer
Business|Economy|Health

Biden administration seeks to wipe consumer medical debt off most credit reports with proposed rule

The Biden administration is pushing to prevent medical debt from being considered in most decisions made over whether someone qualifies to rent an apartment, buy a car or take on a mortgage

Biden administration seeks to wipe consumer medical debt off most credit reports with proposed rule
Health

Being a patient is getting harder in a strained and complex US health care system

Health care delivery experts say patients in the U.S. need more help dealing with a system that is growing increasingly complex

Being a patient is getting harder in a strained and complex US health care system
Business|Health

Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro

Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its hot-selling weight-loss and diabetes treatments, Zepbound and Mounjaro

Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro
Business|Economy|Health

CVS Health chops 2024 forecast as cost struggles with Medicare Advantage persist

CVS Health missed first-quarter expectations and chopped its 2024 outlook more than a dollar below Wall Street’s forecast

CVS Health chops 2024 forecast as cost struggles with Medicare Advantage persist
Business|Health

It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?

The first drug shown to slow Alzheimer’s hit the U.S. market over a year ago, but sales have lagged and diagnosis and treatment remain complicated

It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Business|Health

Insurer delays and denials hamper patients seeking at-home breathing machines

Doctors around the country say insurers are making it harder to get coverage for home ventilators that patients with serious illnesses need as their lungs fail

Insurer delays and denials hamper patients seeking at-home breathing machines
Business|Health

CVS and Walgreens plan to start dispensing abortion pill mifepristone soon

Drugstore chains CVS Health and Walgreens plan to start dispensing the abortion pill mifepristone in a few states

CVS and Walgreens plan to start dispensing abortion pill mifepristone soon
Business|Health

Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024

Eli Lilly rode soaring demand for diabetes and weight-loss treatments to a better-than-expected finish in 2023, and the drugmaker expects momentum to carry into the new year

Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024

Follow